Navigation Links
Bristol-Myers Squibb and WuXi PharmaTech Announce Collaboration for a New Analytical and Stability Testing Facility
Date:3/7/2011

NEW YORK and SHANGHAI, March 7, 2011 /PRNewswire-Asia/ -- Bristol-Myers Squibb Company (NYSE: BMY) and WuXi PharmaTech (NYSE: WX) today announced that they have entered a strategic partnership to conduct stability studies of small-molecule new chemical entities to support global marketing applications.

Under the agreement, WuXi will build, equip and operate a dedicated, fully cGMP-compliant 25,000-square-foot analytical testing facility in Shanghai to store and test stability samples and to perform other services for Bristol-Myers Squibb. WuXi will also employ a dedicated staff for stability testing, sample management, analytical testing, pharmaceutical science, quality assurance, metrology, and other services, including stability data reporting in support of all global dossier submissions by Bristol-Myers Squibb.

"This new agreement expands our already productive relationship with Bristol-Myers Squibb, a valued customer for many years," said Ge Li, Ph.D., chairman and chief executive officer of WuXi PharmaTech. "We will continue to help them to improve their R&D productivity with our innovation-driven, cost-effective and fully integrated R&D service platform."

"WuXi PharmaTech is an important partner for Bristol-Myers Squibb's research and development organization," said Mark Powell, Ph.D., senior vice president, Non-Clinical Development, Bristol-Myers Squibb. "This agreement will expand the scope of our relationship with WuXi and enhance the presence of Bristol-Myers Squibb in China. It is also an example of our R&D organization executing our company's BioPharma model by using selective integration to leverage the strengths and talents of both Bristol-Myers Squibb and a valued partner."

About Bristol-Myers SquibbBristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, developand deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

About WuXi PharmaTechWuXi PharmaTech is a leading pharmaceutical, biotechnology and medical-device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical-device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical-device R&D process. For more information, please visit: http://www.wuxiapptec.com . For more information, please contact:Bristol-Myers SquibbMedia: Jennifer Fron MauerTel:
+1-609-252-6579Investor Relations:Teri LoxamTel:
+1-609-252-3368Timothy PowerTel:   +1-609-252-7509WuXi PharmaTechMedia: Email: Stephanie_Liu@wuxiapptec.comTel:
+86-21-50464362Investor Relations: Email: Ron_Aldridge@wuxiapptec.comTel:
+1-201-585-2048
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bristol-Myers Squibb, New Jersey Childrens Hospital Launch Center for Immune System Disorders & Infectious Diseases Including HIV/AIDS
2. Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
3. Top Bristol-Myers Squibb Executive Joins Patton Boggs
4. Isis Earns $6 Million Milestone Payment From Bristol-Myers Squibb for BMS-PCSK9Rx
5. Bend Research Announces Extension of Drug-Discovery Enablement and Development Services Agreement With Bristol-Myers Squibb
6. Bristol-Myers Squibb Sued for Denying Employees Overtime Pay
7. Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab
8. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
9. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
10. WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Consecutive Year
11. WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... plc (NASDAQ: ENDP ) will announce its second-quarter 2017 ... management team will host a conference call and webcast before the ... The dial-in number to access the call is U.S./ Canada ... 45397076. Please dial in 10 minutes prior to the scheduled start ... the call will be available from August 8, 2017 at 11:30 ...
(Date:7/13/2017)... July 13, 2017 RK Logistics Group, Inc. was ... certification for its Fremont, CA headquarters ... the Tri-Valley and San Jose for ... of Fremont , with its Fremont Innovation District, is ... such a powerful resource to the hundreds of biotech, pharma ...
(Date:7/12/2017)... Lilly and Company (NYSE: LLY ) has entered ... patent litigation in the U.S. District Court for the Eastern ... ® (tadalafil) unit dose patent. This patent was previously ... the agreement, Cialis exclusivity is now expected to end at ... dose patent for Cialis is valid and infringed by companies ...
Breaking Medicine Technology:
(Date:7/24/2017)... , ... July 24, 2017 , ... A CDC study shows that, although people are ... Caucasians (ages 18 to 29), had at least one case of sunburn within the past ... which causes people to ignore the issue. However, only recently have people become conscientious of ...
(Date:7/24/2017)... ... July 24, 2017 , ... The 2017 NCSL International Workshop ... theme focuses on the new ISO/IEC 17025 standards. This marks the first time ... and calibration will be changed. , As an exhibitor, METTLER TOLEDO will ...
(Date:7/24/2017)... ... July 24, 2017 , ... Paul Vitenas, MD, FACS is excited ... plastic surgeons, invited to attend Allergan’s recent meeting with their Plastics Advisory Board. As ... the world, Allergan is bringing a newly defined structure to the aesthetics market. ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... CURE announced that they have enrolled over 100,000 children in their treatment program. ... born every year in areas where treatment is limited or non-existent. Without intervention, ...
(Date:7/24/2017)... Church, VA (PRWEB) , ... July 24, 2017 ... ... figuring out how to change manufacturers future. , The agency is hammering out ... Cures Act, one of the farthest-ranging laws ever to affect FDA-regulated firms. The ...
Breaking Medicine News(10 mins):